Login to Your Account



Mesoblast sees positive data for GVHD cell therapy

By Michael Fitzhugh
Staff Writer

Monday, February 22, 2016

Mesoblast Ltd., the developer of a cell therapy for steroid-refractory acute GVHD, reported that a new analysis of long-term data shows that children treated with the cells demonstrated clinically meaningful responses and significantly increased survival.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription